retatrutide clinical trial safety data 🧬 Explained Retatrutide is one of the most promising investigational peptides currently being studied for weight management and metabolic health. Unlike current GLP-1 medications, Retatrutide activates three hormone receptors: • GLP-1 Retatrutide Results: 24% Weight Loss

What is the evidence regarding the safety of new obesity pharmacotherapies

Both pathway and individual metabolite analysis revealed differential abundance of tryptophan pathway intermediates in PBH, including tryptophan itself and its downstream metabolites kynurenic acid, xanthurenate, and serotonin (Figure 4)

These results were found with the samples solubilised in saliva, but they were subjected to further in vitro simulated gastrointestinal digestion (including treatment with pepsin and pancreatin)

The analysts remained optimistic that this class of drugs will have the ability to overcome supply issues and enjoy sustained uptake. Additionally, they said we are also optimistic that reimbursement will steadily expand for weight loss, achieving over $100 billion in global sales by 2030.

Carlessi R, Chen Y, Rowlands J, Cruzat VF, Keane KN, Egan L, et al

GLP-1s promote insulin release and suppress the production of glucagon in response to eating, thereby lowering blood sugar